 |
|
|
|
Nobivac KC for active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk; to reduce clinical signs induced by B. bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus. Reduction of shedding of B. bronchiseptica has been shown from 3 months after vaccination.
|
|
Presentation
Live freeze-dried vaccine with accompanying diluent.
Each dose of 0.4 ml contains:
at least 108.0 cfu of Bordetella bronchiseptica strain B-C2 and
at least 103.0 TCID50 of canine parainfluenza virus strain Cornell.
Uses
Active immunisation of dogs against Bordetella bronchiseptica and canine parainfluenza virus for periods of increased risk; to reduce clinical signs induced by B. bronchiseptica and canine parainfluenza virus and to reduce shedding of canine parainfluenza virus. Reduction of shedding of B. bronchiseptica has been shown from 3 months after vaccination.
Onset of immunity against Bordetella bronchiseptica has been demonstrated 72 hours after vaccination, and against canine parainfluenza virus three weeks after vaccination.
Duration of immunity: 1 year.
|
|
Dosage and administration
Dogs should be at least 3 weeks of age.
When Nobivac KC is concurrently administered (i.e. not mixed) with another Intervet vaccine as indicated below, dogs should not be younger than the minimum age recommended for the other Intervet vaccine.
Allow the diluent to reach room temperature before use.
Aseptically reconstitute the freeze-dried vaccine with the sterile diluent provided, shake well, replace the needle with the applicator tip and administer 0.4 ml into one nostril. The head of the dog should be held in a normal upright position, place the applicator tip in front of one of the nostrils and carefully administer the whole contents of the syringe into this nostril.
One dose should be given at least 72 hours prior to each period of anticipated risk, e.g. temporary kennelling. In the case of repeated and/or continuous risk, annual re-vaccination is recommended.
|
|
Contra-indications, warnings, etc
Particularly in very young susceptible puppies, mild discharges from the eyes and nose can occur from the day after vaccination, sometimes accompanied by sneezing and coughing. Signs are generally transient, but in occasional cases may persist for up to four weeks. In animals which show more severe signs, appropriate antibiotic treatment may be indicated.
Only healthy dogs should be vaccinated. Cats, pigs and unvaccinated dogs may react to the vaccine strains with mild and transient respiratory signs. Other animals, like rabbits and small rodents, have not been tested.
Do not administer in conjunction with other intranasal treatments or during antibiotic treatment. No information is available on the safety and efficacy from the use of this vaccine with any other except the live vaccines of the Nobivac series against canine distemper; canine contagious hepatitis caused by canine adenovirus type 1; respiratory disease caused by canine adenovirus type 2 and canine parvovirus disease. It is therefore recommended that no other vaccine should be administered within 14 days before or after vaccination with Nobivac KC.
In case antibiotics are administered within one week after vaccination, the vaccination should be repeated after the antibiotic treatment is finished.
Immunocompromised individuals should avoid any contact with the vaccine and vaccinated dogs for up to six weeks after vaccination.
For animal treatment only. Keep out of reach and sight of children.
Pharmaceutical precautions
Store between +2°C and +8°C. Allow the vaccine and diluent to reach room temperature. The vaccine should be used within 1 hour after reconstitution.
Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant in accordance with national requirements.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
Cartons of 5 or 25 single dose vials with diluent.
Further information
The vaccine can be used during pregnancy.
A good immune response is reliant on the reaction of an immunogenic agent and a fully competent immune system. Immunogenicity of the vaccine antigen will be reduced by poor storage or inappropriate administration. Immuno-competence of the animal may be compromised by a variety of factors including poor health, nutritional status, genetic factors, concurrent drug therapy and stress.
Marketing authorisation number
Vm 06376/4026.
UK authorised veterinary medicinal product.
Marketing authorisation holder
Intervet International bv
Wim de Körverstraat 35
PO Box 31
5830 AA Boxmeer
The Netherlands
|
|
|
